Alexion's Pipeline Rebuild Plan Targets Wilson's Liver Drug, More M&A Likely
Swedish target's sole product WTX101 is in Phase III trials for treating Wilson Disease. Alexion says expect more deals.
You may also be interested in...
Alexion’s third deal this year brings privately held Syntimmune and its Phase Ib/IIa candidate for three IgG-mediated rare disorders, including warm autoimmune hemolytic anemia, for a $400m upfront price tag.
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.